# P PhillipCapital

# TCI Limited (TRPC IN)

# Strong recovery in Supply Chain

# INDIA | LOGISTICS | Quarterly Update

# Top takeaways from 4QFY21

- ✓ Results better than expectations. Recovery across all business segments.
- ✓ Benefit of multimodal solutions and an improvement in margins with cost control.

#### **Key highlights**

Consolidated revenue increased by 27.3%yoy to Rs 7.96bn (5.3% higher than estimates of Rs 7.56bn). Gross margins impacted marginally by 20bps yoy to 19.5% in 4QFY21. EBITDA increased by 47.6% yoy (+8.4% qoq) to Rs 856mn, higher than estimates of Rs 790mn. EBITDA margins increased from 9.3% in 4QFY20 to 10.7% in 4QFY21. Interest cost declined by 30%yoy to Rs 56mn with improved cashflow and debt repayment. PBT increased by 72.2% yoy to Rs 637.3mn. Adjusted profit at Rs 564mn in 4QFY21 vs estimates of Rs 473mn.

#### Conference call takeaways

- Freight division revenue up by 20.0%yoy (up +18.1% qoq) to Rs 3.87bn; Supply Chain revenue increased by 40.7%yoy (up -0.2% qoq) to Rs 2.9bn; Seaway's revenue grew by 24.4%yoy (up +25.4%qoq) to Rs 1.3bn.
- EBITDA in freight division grew by 27.0%yoy to Rs 172mn with margin improvement of 20bps yoy to 4.4% in 4QFY21; EBITDA in SCM grew by 69.1%yoy to Rs 328mn and in seaways increased by 40.9%yoy to Rs 434mn. EBITDA margins in SCM and Seaways improved by 190bps yoy to 11.2% and 390bps yoy to 33.4% respectively in 4QFY21.
- Freight division has reached c.95% of pre-covid level with pent up demand and recovery in MSME in 4QFY21. Less Than Truck Load (LTL) is c. 31% of freight business supporting the margins and expect LTL share to increase to 40% by 2025.
- Integrated logistics solution capability has shown effectiveness and strength. Growth in SCM was supported by demand revival and growth in Pharma, Agri, E-commerce & FMCG. SCM margins improved due better revenue realization and management is hopeful of strong growth in SCM with focus on profitability.
- JV performance: TCI Concor operating asset light rail operations reported revenue growth of 71%yoy to Rs 3.2bn in FY21. Transystem focused on automotive logistics reported revenue decline of 19.2%yoy to Rs 3.5bn in FY21. TCI Cold chain reported revenue of Rs 363mn in FY21 compared to Rs 258mn in FY20.
- It had capital expenditure of Rs 1.1bn in FY21 and expect capex of Rs 2.2bn in FY22. Capex is mainly for developing hub centres and warehouses (Rs 640mn), trucks (Rs 340mn) and ship addition (Rs 800mn).

**Outlook and valuation:** At CMP, stock trades at 12.0x our FY23 earnings. We have revised earnings considering improved operating performance. TCI has a strong history of maintaining growth in different economic cycles. It is best placed to provide a cost-effective solution to the customized needs of its clients due to its national network (historical asset base at strategic locations) and multimodal capabilities. The level playing field for organized players post GST and E-way Bill is helping to gain market share. We maintain valuation at 15xFY23EPS to arrive at a target of Rs 458 (earlier Rs 390).

# 26 May 2021

# **BUY (Maintain)**

CMP RS 366 / TARGET Rs 458 (+25%)

#### **COMPANY DATA**

O/S SHARES (MN) :	77
MARKET CAP (RSBN):	24
MARKET CAP (USDBN):	0.3
52 - WK HI/LO (RS) :	319 / 146
LIQUIDITY 3M (USDMN):	0.4
PAR VALUE (RS):	10

#### **SHARE HOLDING PATTERN, %**

	Mar 21	Dec 20	Sep 20
PROMOTERS	66.8	66.8	66.7
DII	12.4	12.4	12.2
FII	1.5	1.5	1.6
OTHERS	19.2	19.2	19.5

#### **KEY FINANCIALS**

Rs mn	FY21	FY22E	FY23E
Net Sales	28024	33483	37768
EBIDTA	2612	3186	3569
Net Profit	1602	2005	2345
EPS, Rs	20.8	26.0	30.4
PER, x	17.6	14.1	12.0
EV/EBIDTA, x	11.8	9.8	8.8
PBV, x	2.4	2.1	1.8
ROE, %	13.7	14.9	15.0
Debt/Equity (%)	0.3	0.2	0.2

#### **CHANGE IN ESTIMATES**

	Revised	Est	% Rev	ision
Rs mn	FY22E	FY23E	FY22E	FY23E
Revenue	33,483	37,768	6%	8%
EBITDA	3,186	3,569	9%	12%
Core PAT	2,005	2,345	13%	17%
EPS (Rs)	26.0	30.4	13%	17%

Vikram Suryavanshi, Research Analyst (022 6246 4111) vsuryavanshi@philipcapital.in

Consolidated (Rs mn)	4QFY21	4QFY20	yoy	3QFY21	qoq	vs. expect.	Comments
					growth %	%	
Revenue	7966	6257	27.3	7152	11.4	5.3	Freight +20.0%yoy; SCM +40.7%yoy; Seaways +24.4%yoy
EBITDA	856	580	47.6	754	13.4	8.4	Revenue mix, Cost control
EBITDA margins	10.7%	9.3%	147bps	10.5%	19bps		Recovery in margins
Other income	105	67		86	22.0	24.0	
Depreciation	268	197	36.2	220	21.6	16.4	Capex of Rs 1.1bn in FY21
Interest	56	80	-29.8	58	-3.8	-6.7	
PBT	637.3	370.0	72.2	562.3	13.3	9.0	
PAT	564	313	80.3	505	11.7	19.1	



Consolidated					
Year End March (Rs mn)	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21
Revenue	6257	3280	6122	7152	7966
Operating expense	5025	2587	4976	5760	6416
Opex as % of sales	80.3%	78.9%	81.3%	80.5%	80.5%
Employee	408	289	329	359	425
Other expenses	245	126	227	278	271
EBITDA	580	279	590	754	856
EBITDA margins (%)	9.3%	8.5%	9.6%	10.5%	10.7%
Other Income	66.6	89.0	70.8	86.4	105.4
Depreciation	196.6	195.2	197.9	220.2	267.7
Interest	79.8	69.6	63.7	58.2	56.0
PBT	370.0	102.7	399.3	562.3	637.3
Tax	57.2	4.1	79.3	57.5	73.4
Tax rate (%)	15.5%	4.0%	19.9%	10.2%	11.5%
Adj PAT	313	99	320	505	564
Extraordinary	0.0	1.4	5.2	-104.3	-35.3
Reported PAT	313	100	325	401	529
EPS (Rs)	4.1	1.3	4.2	6.6	7.3

Segmental details					
Standalone	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21
Freight Division	3227	1578	2781	3278	3871
Supply chain	2078	1056	2467	2929	2924
Seaways	1046	682	932	1038	1301
Energy	6	14	17	3	5
EBIT (Rs mn)					
Freight Division	117	20	98	137	161
Supply chain	101	31	164	198	203
Seaways	225	41	155	235	305
Energy	-1	8	11	-3	-1
EBIT (%)					
Freight Division	3.6%	1.3%	3.5%	4.2%	4.1%
Supply chain	4.9%	3.0%	6.6%	6.8%	6.9%
Seaways	21.5%	6.0%	16.6%	22.6%	23.5%

Source: Company, PhillipCapital India Research

# **Financials**

### **Income Statement**

FY20	FY21	FY22E	FY23E
27,178	28,024	33,483	37,768
-1	3	19	13
-22,143	-22,972	-27,288	-30,781
-1,572	-1,455	-1,875	-2,115
-1,058	-984	-1,134	-1,303
2,405	2,612	3,186	3,569
(3.6)	8.6	21.9	12.0
-825	-928	-960	-1,000
1,580	1,684	2,226	2,569
(8.2)	6.6	32.1	15.4
5.8	6.0	6.6	6.8
-343	-267	-268	-288
201	255	204	215
-99	-131	0	0
1,340	1,541	2,162	2,495
-159	-238	-368	-424
1,181	1,303	1,795	2,071
243	168	211	274
1,424	1,471	2,005	2,345
4.3	5.2	25.2	16.9
1,523	1,602	2,005	2,345
77	77	77	77
	27,178	27,178 28,024 -1 3 -22,143 -22,972 -1,572 -1,455 -1,058 -984 2,405 2,612 (3.6) 8.6 -825 -928 1,580 1,684 (8.2) 6.6 5.8 6.0 -343 -267 201 255 -99 -131 1,340 1,541 -159 -238 1,181 1,303 243 168 1,424 1,471 4.3 5.2 1,523 1,602	27,178         28,024         33,483           -1         3         19           -22,143         -22,972         -27,288           -1,572         -1,455         -1,875           -1,058         -984         -1,134           2,405         2,612         3,186           (3.6)         8.6         21.9           -825         -928         -960           1,580         1,684         2,226           (8.2)         6.6         32.1           5.8         6.0         6.6           -343         -267         -268           201         255         204           -99         -131         0           1,340         1,541         2,162           -159         -238         -368           1,181         1,303         1,795           243         168         211           1,424         1,471         2,005           4.3         5.2         25.2           1,523         1,602         2,005

# **Balance Sheet**

Y/E Mar, Rs mn	FY20	FY21	FY22E	FY23E
Cash & bank	259	395	322	431
Debtors	4,873	5,110	6,238	7,243
Inventory	66	71	78	86
Loans & advances	268	265	317	355
Other current assets	1,121	1,340	1,474	1,621
Total current assets	6,586	7,181	8,429	9,737
Investments	1,799	1,912	2,328	2,673
Gross fixed assets	10,527	11,380	12,721	14,521
Less: Depreciation	-3,043	-3,971	-4,931	-5,931
Add: Capital WIP	216	52	183	183
Net fixed assets	7,699	7,461	7,973	8,773
Non-current assets	234	638	750	880
Total assets	16,319	17,192	19,480	22,064
Current liabilities	1,934	2,192	2,477	2,587
Provisions	102	86	94	104
Total current liabilities	2,036	2,278	2,571	2,691
Non-current liabilities	3,988	3,130	3,423	3,681
Total liabilities	6,024	5,408	5,994	6,372
Paid-up capital	154	154	154	154
Reserves & surplus	10,084	11,543	13,275	15,481
Shareholders' equity	10,295	11,783	13,486	15,692
Total equity & liabilities	16,319	17,192	19,480	22,064

Source: Company, PhillipCapital India Research Estimates

# Cash Flow


Y/E Mar, Rs mn	FY20	FY21	FY22E	FY23E
Pre-tax profit	1,340	1,541	2,162	2,495
Depreciation	825	928	960	1,000
Chg in working capital	-315	-604	-1,149	-1,219
Total tax paid	-417	51	-368	-424
Cash flow from operating activities	1,432	1,916	1,606	1,853
Capital expenditure	-1,216	-690	-1,472	-1,800
Chg in investments	112	-113	-415	-346
Cash flow from investing activities	-1,104	-803	-1,888	-2,146
Free cash flow	329	1,113	-282	-293
Equity raised/(repaid)	504	597	336	470
Debt raised/(repaid)	-405	-1,147	293	258
Dividend (incl. tax)	-101	-155	-130	-129
Cash flow from financing activities	246	-507	679	873
Net chg in cash	575	606	398	579

### **Valuation Ratios**

	FY20	FY21	FY22E	FY23E
Per Share data				
EPS (INR)	19.8	20.8	26.0	30.4
Growth, %	4.1	4.8	25.2	16.9
Book NAV/share (INR)	133.3	151.7	174.2	202.8
FDEPS (INR)	19.8	20.8	26.0	30.4
CEPS (INR)	31.9	34.5	38.5	43.4
CFPS (INR)	19.1	26.8	19.6	22.9
DPS (INR)	1.5	1.5	1.5	1.5
Return ratios				
Return on assets (%)	9.5	9.4	11.2	11.4
Return on equity (%)	14.9	13.7	14.9	15.0
Return on capital employed (%)	10.9	10.8	13.0	13.0
Turnover ratios				
Asset turnover (x)	2.3	2.3	2.6	2.6
Sales/Total assets (x)	1.7	1.7	1.8	1.8
Sales/Net FA (x)	3.6	3.7	4.3	4.5
Working capital/Sales (x)	0.2	0.2	0.2	0.2
Fixed capital/Sales (x)	65.4	66.6	68.0	70.0
Receivable days	0.9	0.9	0.9	0.8
Payable days	9.4	10.9	9.9	9.9
Working capital days	57.6	58.7	60.3	63.9
Liquidity ratios				
Current ratio (x)	3.2	3.2	3.3	3.6
Quick ratio (x)	3.2	3.1	3.2	3.6
Interest cover (x)	4.6	6.3	8.3	8.9
Total debt/Equity (%)	41.0	26.1	24.9	23.1
Net debt/Equity (%)	38.5	22.7	22.5	20.3
Valuation				
PER (x)	18.5	17.6	14.1	12.0
PEG (x) - y-o-y growth	4.5	3.7	0.6	0.7
Price/Book (x)	2.7	2.4	2.1	1.8
EV/Net sales (x)	1.2	1.1	0.9	0.8
EV/EBITDA (x)	13.3	11.8	9.8	8.8
EV/EBIT (x)	20.3	18.3	14.0	12.2



# **Stock Price, Price Target and Rating History**



## Rating Methodology

We rate stock on absolute return basis. Our target price for the stocks has an investment horizon of one year. We have different threshold for large market capitalisation stock and Mid/small market capitalisation stock. The categorisation of stock based on market capitalisation is as per the SEBI requirement.

# Large cap stocks

Rating	Criteria	Definition
BUY	>= +10%	Target price is equal to or more than 10% of current market price
NEUTRAL	-10% > to < +10%	Target price is less than +10% but more than -10%
SELL	<= -10%	Target price is less than or equal to -10%.

#### Mid cap and Small cap stocks

Rating	Criteria	Definition
BUY	>= +15%	Target price is equal to or more than 15% of current market price
NEUTRAL	-15% > to < +15%	Target price is less than +15% but more than -15%
SELL	<= -15%	Target price is less than or equal to -15%.

# **Disclosures and Disclaimers**

PhillipCapital (India) Pvt. Ltd. has three independent equity research groups: Institutional Equities, Institutional Equity Derivatives, and Private Client Group. This report has been prepared by Institutional Equities Group. The views and opinions expressed in this document may, may not match, or may be contrary at times with the views, estimates, rating, and target price of the other equity research groups of PhillipCapital (India) Pvt. Ltd.

This report is issued by PhillipCapital (India) Pvt. Ltd., which is regulated by the SEBI. PhillipCapital (India) Pvt. Ltd. is a subsidiary of Phillip (Mauritius) Pvt. Ltd. References to "PCIPL" in this report shall mean PhillipCapital (India) Pvt. Ltd unless otherwise stated. This report is prepared and distributed by PCIPL for information purposes only, and neither the information contained herein, nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security, investment, or derivatives. The information and opinions contained in the report were considered by PCIPL to be valid when published. The report also contains information provided to PCIPL by third parties. The source of such information will usually be disclosed in the report. Whilst PCIPL has taken all reasonable steps to ensure that this information is correct, PCIPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and PCIPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

This report does not regard the specific investment objectives, financial situation, and the particular needs of any specific person who may receive this report. Investors must undertake independent analysis with their own legal, tax, and financial advisors and reach their own conclusions regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realised. Under no circumstances can it be used or considered as an offer to sell or as a solicitation of any offer to buy or sell the securities mentioned within it. The information contained in the research reports may have been taken from trade and statistical services and other sources,



#### TCI LIMITED QUARTERLY UPDATE

which PCIL believe is reliable. PhillipCapital (India) Pvt. Ltd. or any of its group/associate/affiliate companies do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice.

Important: These disclosures and disclaimers must be read in conjunction with the research report of which it forms part. Receipt and use of the research report is subject to all aspects of these disclosures and disclaimers. Additional information about the issuers and securities discussed in this research report is available on request.

Certifications: The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known conflict of interest and no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

#### Additional Disclosures of Interest:

Unless specifically mentioned in Point No. 9 below:

- 1. The Research Analyst(s), PCIL, or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. The Research Analyst, PCIL or its associates or relatives of the Research Analyst affiliates collectively do not hold more than 1% of the securities of the company (ies)covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. The Research Analyst, his/her associate, his/her relative, and PCIL, do not have any other material conflict of interest at the time of publication of this research report.
- 4. The Research Analyst, PCIL, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- 5. The Research Analyst, PCIL or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report.
- 6. PCIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- 7. The Research Analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
- 8. The Research Analyst and PCIL has not been engaged in market making activity for the company(ies) covered in the Research report.
- 9. Details of PCIL, Research Analyst and its associates pertaining to the companies covered in the Research report:

Sr. no.	Particulars	Yes/No
1	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for	
	investment banking transaction by PCIL	
2	Whether Research Analyst, PCIL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1% of	No
	the company(ies) covered in the Research report	
3	Whether compensation has been received by PCIL or its associates from the company(ies) covered in the Research report	No
4	PCIL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the	No
	company(ies) covered in the Research report	
5	Research Analyst, his associate, PCIL or its associates have received compensation for investment banking or merchant banking or	No
	brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve	
	months	

Independence: PhillipCapital (India) Pvt. Ltd. has not had an investment banking relationship with, and has not received any compensation for investment banking services from, the subject issuers in the past twelve (12) months, and PhillipCapital (India) Pvt. Ltd does not anticipate receiving or intend to seek compensation for investment banking services from the subject issuers in the next three (3) months. PhillipCapital (India) Pvt. Ltd is not a market maker in the securities mentioned in this research report, although it, or its affiliates/employees, may have positions in, purchase or sell, or be materially interested in any of the securities covered in the report.

Suitability and Risks: This research report is for informational purposes only and is not tailored to the specific investment objectives, financial situation or particular requirements of any individual recipient hereof. Certain securities may give rise to substantial risks and may not be suitable for certain investors. Each investor must make its own determination as to the appropriateness of any securities referred to in this research report based upon the legal, tax and accounting considerations applicable to such investor and its own investment objectives or strategy, its financial situation and its investing experience. The value of any security may be positively or adversely affected by changes in foreign exchange or interest rates, as well as by other financial, economic, or political factors. Past performance is not necessarily indicative of future performance or results.

Sources, Completeness and Accuracy: The material herein is based upon information obtained from sources that PCIPL and the research analyst believe to be reliable, but neither PCIPL nor the research analyst represents or guarantees that the information contained herein is accurate or complete and it should not be relied upon as such. Opinions expressed herein are current opinions as of the date appearing on this material, and are subject to change without notice. Furthermore, PCIPL is under no obligation to update or keep the information current. Without limiting any of the foregoing, in no event shall PCIL, any of its affiliates/employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind including but not limited to any direct or consequential loss or damage, however arising, from the use of this document.

Copyright: The copyright in this research report belongs exclusively to PCIPL. All rights are reserved. Any unauthorised use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the PCIPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

Caution: Risk of loss in trading/investment can be substantial and even more than the amount / margin given by you. Investment in securities market are subject to market risks, you are requested to read all the related documents carefully before investing. You should carefully consider whether trading/investment is appropriate for you in light of your experience, objectives, financial resources and other relevant circumstances. PhillipCapital and any of its employees, directors, associates, group entities, or affiliates shall not be liable for losses, if any, incurred by you. You are further cautioned that trading/investments in financial markets are subject to market risks and are advised to seek independent third party trading/investment advice outside PhillipCapital/group/associates/affiliates/directors/employees before and during your trading/investment. There is no guarantee/assurance as to returns or profits or capital protection or appreciation. PhillipCapital and any of its employees, directors, associates, and/or employees, directors, associates of PhillipCapital's group entities or affiliates is not inducing you for trading/investing in the financial market(s). Trading/Investment decision is your sole responsibility. You must also read the Risk Disclosure Document and Do's and Don'ts before investing.

Kindly note that past performance is not necessarily a guide to future performance.



# TCI LIMITED QUARTERLY UPDATE

For Detailed Disclaimer: Please visit our website www.phillipcapital.in

#### **IMPORTANT DISCLOSURES FOR U.S. PERSONS**

This research report is a product of PhillipCapital (India) Pvt. Ltd. which is the employer of the research analyst(s) who has prepared the research report. PhillipCapital (India) Pvt Ltd. is authorized to engage in securities activities in India. PHILLIPCAP is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not a Major Institutional Investor.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc, 40 Wall Street 59th Floor, New York NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through PHILLIPCAP. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

#### **Ownership and Material Conflicts of Interest**

Rosenblatt Securities Inc. or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Rosenblatt Securities Inc, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Rosenblatt Securities Inc. is not aware of any material conflict of interest as of the date of this publication

#### **Compensation and Investment Banking Activities**

Rosenblatt Securities Inc. or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

#### **Additional Disclosures**

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither PHILLIPCAP nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

PHILLIPCAP may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of PHILLIPCAP.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by PHILLIPCAP with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of PHILLIPCAP and PHILLIPCAP accepts no liability whatsoever for the actions of third parties in this respect.

#### PhillipCapital (India) Pvt. Ltd.

Registered office: 18th floor, Urmi Estate, Ganpatrao Kadam Marg, Lower Parel (West), Mumbai – 400013, India.